Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 1:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 273 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: MESNA Clear all
Completed Phase 1 Interventional

Stem Cell Transplant to Treat Patients With Systemic Sclerosis

NCT00058578
View directory record Official record
Conditions
Systemic Sclerosis
Interventions
Cyclophosphamide, Mesna, G-CSF, Leukopheresis, Total Body Irradiation
Drug · Procedure
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 20, 2026, 1:04 PM EDT
Not listed Phase 1Phase 2 Interventional

Tandem Peripheral Blood Stem Cell (PBSC) Rescue for High Risk Solid Tumors

NCT00179816
View directory record Official record
Conditions
Ewing's Sarcoma, Soft Tissue Sarcoma, Hepatoblastoma, Hodgkin's Disease, Germ Cell Tumor
Interventions
High-Dose Chemotherapy with Tandem PBSC Rescue.
Drug
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
Up to 21 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 11, 2010 · Synced Oct 20, 2026, 1:04 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients

NCT03745326
View directory record Official record
Conditions
Gastrointestinal Cancer, Pancreatic Cancer, Gastric Cancer, Colon Cancer, Rectal Cancer
Interventions
Cyclophosphamide, Fludarabine, Aldesleukin, anti-Kirsten rat sarcoma virus (KRAS) Glycine(G) to Aspartic Acid(D) substitution at codon 12 peripheral blood lymphocytes (PBL), EKG, CT, MRI, PET, Chest x-ray, Photography
Drug · Biological · Diagnostic Test + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 72 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 20, 2026, 1:04 PM EDT
Completed Phase 2 Interventional Results available

Myeloablative Haploidentical BMT With Post-transplant Cyclophosphamide for Pediatric Patients With Hematologic Malignancies

NCT02120157
View directory record Official record
Conditions
Myeloablative Conditioning, HLA-mismatched Bone Marrow Transplantation, Graft Survival, Transplantation, Bone Marrow
Interventions
Cyclophosphamide, TBI, Busulfan, Unmanipulated Bone Marrow, Tacrolimus, Mycophenolate mofetil
Drug · Radiation · Other
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
6 Months to 25 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
7
States / cities
Aurora, Colorado • Wilmington, Delaware • St. Petersburg, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2021 · Synced Oct 20, 2026, 1:04 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Panobinostat Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Compared With ICE For Relapsed Hodgkin Lymphoma

NCT01169636
View directory record Official record
Conditions
Hodgkin's Lymphoma
Interventions
Panobinostat, Ifosfamide, Mesna, Carboplatin, Etoposide, Pegfilgrastim
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
16 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 6, 2021 · Synced Oct 20, 2026, 1:04 PM EDT
Completed Phase 1Phase 2 Interventional

Ifosfamide, Teniposide, and Paclitaxel in Treating Patients With Relapsed Non-Hodgkin's Lymphoma

NCT00004916
View directory record Official record
Conditions
Lymphoma
Interventions
ifosfamide, paclitaxel, teniposide, peripheral blood stem cell transplantation
Drug · Procedure
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 6, 2012 · Synced Oct 20, 2026, 1:04 PM EDT
Recruiting No phase listed Observational

Umbilical Cord Blood Transplantation From Unrelated Donors

NCT03016806
View directory record Official record
Conditions
Acute Leukemia, Immune Deficiency Disorder, Congenital Hematological Disorder, Metabolism Disorder, Aplastic Anemia, Myelodysplastic Syndromes, Chronic Leukemia, Lymphoma, Multiple Myeloma, Solid Tumor
Interventions
Total Body Irradiation 1200 cGy, Total Body Irradiation 200 cGy, Cyclophosphamide, Mesna, Cord Blood Infusion, Busulfan, Fludarabine, Melphalan
Radiation · Drug · Procedure
Lead sponsor
University of Rochester
Other
Eligibility
2 Months to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Oct 10, 2025 · Synced Oct 20, 2026, 1:04 PM EDT
Terminated Phase 2 Interventional Results available

Donor Umbilical Cord Blood Natural Killer Cells, Aldesleukin and Umbilical Cord Blood Transplant in Patients With Refractory Hematologic Cancers.

NCT00354172
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndromes
Interventions
aldesleukin, filgrastim, natural killer cell (NK) therapy, cyclophosphamide, cyclosporine, fludarabine phosphate, methylprednisolone, mycophenolate mofetil, Umbilical Cord Blood Transplantation (UCBT), Total body irradiation (TBI)
Biological · Drug · Procedure + 1 more
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 45 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 28, 2017 · Synced Oct 20, 2026, 1:04 PM EDT
Completed Phase 3 Interventional

SWOG-9321 Melphalan, TBI, and Transplant vs Combo Chemo in Untreated Myeloma

NCT00002548
View directory record Official record
Conditions
Multiple Myeloma
Interventions
recombinant interferon alfa, carmustine, cyclophosphamide, dexamethasone, doxorubicin hydrochloride, melphalan, prednisone, vincristine sulfate, allogeneic bone marrow transplantation, autologous bone marrow transplantation, peripheral blood stem cell transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years to 70 Years
Enrollment
899 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2006
U.S. locations
34
States / cities
Scottsdale, Arizona • Denver, Colorado • Tampa, Florida + 25 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2015 · Synced Oct 20, 2026, 1:04 PM EDT
Completed Phase 1Phase 2 Interventional

Liver Transplantation With Tregs at MGH

NCT03577431
View directory record Official record
Conditions
Liver Transplant
Interventions
arTreg-CSB, leukapheresis, cyclophosphamide, mesna, everolimus
Biological · Procedure · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 20, 2026, 1:04 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Cardiac Safe Transplants for Systemic Sclerosis

NCT03593902
View directory record Official record
Conditions
Systemic Sclerosis, Scleroderma
Interventions
Rituximab, Fludarabine, Cyclophosphamide, Mesna, rATG, Methylprednisolone, G-CSF, IVIg, Autologous Stem Cells
Drug · Biological
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 12, 2020 · Synced Oct 20, 2026, 1:04 PM EDT
Completed Phase 1Phase 2 Interventional Results available

RAD001 Study in Treatment of Relapsed or Refractory Acute Lymphocytic Leukemia

NCT00968253
View directory record Official record
Conditions
Leukemia, Acute Lymphocytic Leukemia
Interventions
Everolimus (RAD001), Cyclophosphamide, Vincristine, Doxorubicin, Dexamethasone, Mesna, Methotrexate, Ara-C (Cytarabine), Methylprednisone, G-CSF
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
10 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 27, 2019 · Synced Oct 20, 2026, 1:04 PM EDT
Completed Phase 2 Interventional Results available

R-MACLO-IVAM and Thalidomide in Untreated Mantle Cell Lymphoma

NCT00450801
View directory record Official record
Conditions
Lymphoma
Interventions
Rituximab, Cyclophosphamide, Cytarabine, Doxorubicin, Etoposide, Ifosfamide, Leucovorin, Methotrexate, Thalidomide, Vincristine, Mesna, Filgrastim (G-CSF), Granisetron, Decadron
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2015
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 10, 2015 · Synced Oct 20, 2026, 1:04 PM EDT
Completed Phase 2 Interventional

Combination Chemotherapy, Bone Marrow Transplantation, and Radiation Therapy in Treating Infants With Acute Lymphoblastic Leukemia

NCT00002785
View directory record Official record
Conditions
Leukemia
Interventions
filgrastim, asparaginase, cyclophosphamide, cyclosporine, cytarabine, daunorubicin hydrochloride, dexamethasone, etoposide, leucovorin calcium, mercaptopurine, mesna, methotrexate, methylprednisolone, pegaspargase, prednisone, therapeutic hydrocortisone, vincristine sulfate, allogeneic bone marrow transplantation, low-LET cobalt-60 gamma ray therapy, low-LET photon therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 1 Year
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2007
U.S. locations
30
States / cities
Long Beach, California • Los Angeles, California • Orange, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2014 · Synced Oct 20, 2026, 1:04 PM EDT
Completed Phase 1 Interventional

Fucosylated T Cells for Graft Versus Host Disease (GVHD) Prevention

NCT02423915
View directory record Official record
Conditions
Leukemia, Lymphoma
Interventions
Rituximab, Fludarabine, Cyclophosphamide, Total Body Radiation, Fucosylated Regulatory T Cells, Cord Blood Infusions, Mycophenolate mofetil, Sirolimus, Bone Marrow Aspiration, G-CSF, Non-Fucosylated Regulatory T Cells
Drug · Radiation · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 80 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 8, 2021 · Synced Oct 20, 2026, 1:04 PM EDT
Completed Phase 2 Interventional Results available

Phase II Study of Metastatic Cancer That Overexpresses P53 Using Lymphodepleting Conditioning Followed by Infusion of Anti-P53 TCR-Gene Engineered Lymphocytes

NCT00393029
View directory record Official record
Conditions
Anti-p53 TCR-Gene
Interventions
anti-protein 53 or tumor protein 53 (p53) T-cell receptor transduced peripheral blood lymphocytes, aldesleukin, filgrastim, cyclophosphamide, fludarabine phosphate
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 15, 2011 · Synced Oct 20, 2026, 1:04 PM EDT
Completed Phase 2 Interventional Results available

Chemotherapy, Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple Myeloma

NCT00006184
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Myeloma Immunoglobulin Idiotype Vaccine, Bortezomib, Cyclophosphamide, Cyclosporine, Doxorubicin hydrochloride, Etoposide, Fludarabine phosphate, Prednisone, Vincristine Sulfate, Methotrexate, GMCSF (granulocyte macrophage colony stimulating factor), GCSF (granulocyte colony stimulating factor)
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 20, 2017 · Synced Oct 20, 2026, 1:04 PM EDT
Withdrawn Phase 2 Interventional

Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Blastic Phase Chronic Myelogenous Leukemia

NCT01670084
View directory record Official record
Conditions
B-cell Adult Acute Lymphoblastic Leukemia, Blastic Phase Chronic Myelogenous Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia, Untreated Adult Acute Lymphoblastic Leukemia
Interventions
nilotinib, rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, methotrexate, cytarabine, prednisone, mesna, dexamethasone, leucovorin calcium
Drug · Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
2
States / cities
Scottsdale, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 30, 2015 · Synced Oct 20, 2026, 1:04 PM EDT
Completed Phase 1 Interventional

Sorafenib, Epirubicin, Ifosfamide, and Radiation Therapy Followed By Surgery in Treating Patients With High-Risk Stage II or Stage III Soft Tissue Sarcoma

NCT00822848
View directory record Official record
Conditions
Sarcoma
Interventions
epirubicin hydrochloride, ifosfamide, sorafenib tosylate, immunoenzyme technique, immunohistochemistry staining method, laboratory biomarker analysis, adjuvant therapy, neoadjuvant therapy, therapeutic conventional surgery, hypofractionated radiation therapy
Drug · Other · Procedure + 1 more
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
15 Years to 120 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 7, 2018 · Synced Oct 20, 2026, 1:04 PM EDT
Terminated Phase 1 Interventional

Neoadjuvant ADI-PEG 20 + Ifosfamide + Radiotherapy in Soft Tissue Sarcoma

NCT05813327
View directory record Official record
Conditions
Soft Tissue Sarcoma, Sts, Sarcoma,Soft Tissue
Interventions
ADI PEG20, Ifosfamide, Radiotherapy, Mesna
Drug · Radiation
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 20, 2026, 1:04 PM EDT
Terminated Not applicable Interventional Results available

Allogeneic Stem Cell Transplantation, Severe Homzygous 0/+Thalassemia or Sever Variants of Beta 0/+ Thalassemia, THALLO

NCT00578292
View directory record Official record
Conditions
Thalassemia
Interventions
Busulfan, Fludarabine, Campath 1H, Cyclophosphamide, MESNA
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Up to 64 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 1, 2020 · Synced Oct 20, 2026, 1:04 PM EDT
Completed Phase 2 Interventional Results available

Randomized Double Cord Blood Transplant Study

NCT00067002
View directory record Official record
Conditions
Leukemia, Lymphocytic, Acute, Leukemia, Myelocytic, Acute, Leukemia, Myeloid, Chronic, Lymphoma, Non-Hodgkin
Interventions
Expanded allogeneic cord blood (CB), One Unmanipulated and One Expanded Cord Blood Unit, Rituxan, Melphalan, Thiotepa, Fludarabine, Cyclophosphamide, Mesna, Total body irradiation (TBI)
Procedure · Drug · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
1 Month to 80 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 1, 2019 · Synced Oct 20, 2026, 1:04 PM EDT
Recruiting Phase 2 Interventional

Haploidentical HCT for Severe Aplastic Anemia

NCT04558736
View directory record Official record
Conditions
Aplastic Anemia, Bone Marrow Failure Syndrome
Interventions
Anti-Thymocyte Globulin (Rabbit), Fludarabine, Cyclophosphamide, Mesna, G-CSF, Total Lymphoid Irradiation (TLI), CliniMACS, HPC, A Infusion, CD45RA-depleted DLI
Drug · Radiation · Device + 1 more
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 20, 2026, 1:04 PM EDT
Completed Phase 3 Interventional

Comparison of Combination Chemotherapy Regimens in Treating Patients With Ewing's Sarcoma or Neuroectodermal Tumor

NCT00006734
View directory record Official record
Conditions
Sarcoma
Interventions
filgrastim, cyclophosphamide, doxorubicin hydrochloride, etoposide, ifosfamide, vincristine sulfate, adjuvant therapy, conventional surgery, neoadjuvant therapy, brachytherapy, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
0 Years to 50 Years
Enrollment
587 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2023
U.S. locations
212
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 155 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2023 · Synced Oct 20, 2026, 1:04 PM EDT